| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
EDA-DA TFA targets bacterial peptidoglycan (PG), a major component of the bacterial cell wall. As a dipeptide probe, it incorporates into the peptidoglycan structure, allowing labeling and visualization of bacterial cell walls. The alkyne group enables click chemistry conjugation with azide-containing fluorophores or other labels. This allows detection of peptidoglycan synthesis and turnover in bacteria.
|
|---|---|
| ln Vitro |
In vitro activity of EDA-DA TFA is demonstrated by its ability to label bacterial peptidoglycan. As a click chemistry reagent containing an alkyne group, it undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. This allows conjugation to fluorophores or other labels for detection. The compound is used to study bacterial cell wall synthesis and dynamics. Detailed activity data are not extensively documented.
|
| ln Vivo |
In vivo activity of EDA-DA TFA is not applicable, as the compound is a research probe used primarily for in vitro labeling of bacterial peptidoglycan. It may have applications in studying bacterial infections in vivo if combined with appropriate detection methods. However, detailed in vivo data are not available from the search results.
|
| Enzyme Assay |
The in vitro labeling assay for EDA-DA TFA involves incubating bacteria with the probe, which incorporates into peptidoglycan. After labeling, cells are fixed and permeabilized, and click chemistry is performed with an azide-conjugated fluorophore. Labeled peptidoglycan is visualized by fluorescence microscopy or quantified by flow cytometry. Standard protocols include appropriate controls such as untreated bacteria and competition experiments.
|
| Cell Assay |
In vitro cell-based assays for EDA-DA TFA are conducted using bacterial cultures. Bacteria are treated with the probe at various concentrations, and peptidoglycan labeling is assessed by fluorescence microscopy after click chemistry with azide-fluorophore conjugates. Labeling efficiency and specificity are evaluated. Cytotoxicity to bacteria may be assessed by measuring growth inhibition. Standard protocols include appropriate positive and negative controls.
|
| Animal Protocol |
In vivo animal studies for EDA-DA TFA are not extensively documented in the available literature. As a bacterial peptidoglycan labeling probe, it may be used in infection models to study bacterial cell wall synthesis in vivo. However, detailed in vivo protocols and efficacy data are not available from the search results. The compound is intended for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of EDA-DA TFA include a molecular weight of 298.22 and a molecular formula of C10H13F3N2O5. The compound appears as a solid. Purity is reported as 95%+. As a research probe, detailed pharmacokinetic parameters are not applicable. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicity information for EDA-DA TFA is limited. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
EDA-DA TFA is an N-terminally tagged dipeptide probe for labeling bacterial peptidoglycan. It is a click chemistry reagent with an alkyne group for CuAAc with azide-containing molecules. It has MW 298.22 and formula C10H13F3N2O5. It is used to study bacterial cell wall synthesis. It is intended for research use only.
|
| Molecular Formula |
C10H13F3N2O5
|
|---|---|
| Molecular Weight |
298.22
|
| Exact Mass |
298.078
|
| CAS # |
87156-01-2
|
| PubChem CID |
164885338
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
337
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@H](C(=O)O)NC(=O)[C@@H](CC#C)N.C(=O)(C(F)(F)F)O
|
| InChi Key |
BRIXKPONTJDKNO-KGZKBUQUSA-N
|
| InChi Code |
InChI=1S/C8H12N2O3.C2HF3O2/c1-3-4-6(9)7(11)10-5(2)8(12)13;3-2(4,5)1(6)7/h1,5-6H,4,9H2,2H3,(H,10,11)(H,12,13);(H,6,7)/t5-,6-;/m1./s1
|
| Chemical Name |
(2R)-2-[[(2R)-2-aminopent-4-ynoyl]amino]propanoic acid;2,2,2-trifluoroacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL (~335.32 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3532 mL | 16.7661 mL | 33.5323 mL | |
| 5 mM | 0.6706 mL | 3.3532 mL | 6.7065 mL | |
| 10 mM | 0.3353 mL | 1.6766 mL | 3.3532 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
